DaVita's stock leads S&P 500 decliners after Berkshire pares stake. Its soft guidance isn't helping.
DaVita shares were tumbling 13.5% Friday to lead S&P 500 decliners, after Warren Buffett's Berkshire Hathaway pared its stake in the provider of kidney dialysis.
Here's why Warren Buffett dumped $31 million worth of this stock
Warren Buffett, the ‘Oracle of Omaha', managed to attain a roughly $142 billion net worth by consistently outperforming the markets. The Berkshire Hathaway (NYSE: BRK.B) chief executive officer (CEO) and chairman did so by utilizing a careful, level-headed approach to investing.
Warren Buffett's Berkshire Hathaway sells some DaVita; Shares fall on disappointing guidance
DaVita shares tumbled after issuing a weak outlook amid rising care costs, while big investor Berkshire offloaded some shares in a pre-planned agreement.
DaVita Inc. (DVA) Q4 2024 Earnings Call Transcript
DaVita Inc. (NYSE:DVA ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Nic Eliason - Group VP, IR Javier Rodriguez - CEO Joel Ackerman - CFO Conference Call Participants Joanna Gajuk - Bank of America AJ Rice - UBS Pito Chickering - Deutsche Bank Justin Lake - Wolfe Research Andrew Mok - Barclays Ryan Langston - TD Cowen Operator Good evening. My name is Michelle, and I will be your conference facilitator today.
Berkshire sells some DaVita shares, cuts stake to 45%
Berkshire Hathaway said on Thursday night it sold 203,091 shares of DaVita , reducing its stake in the kidney dialysis services provider to about 35.89 million shares, a 45% stake worth nearly $6.4 billion.
DaVita HealthCare (DVA) Beats Q4 Earnings and Revenue Estimates
DaVita HealthCare (DVA) came out with quarterly earnings of $2.24 per share, beating the Zacks Consensus Estimate of $2.21 per share. This compares to earnings of $1.87 per share a year ago.
DaVita forecasts 2025 profit below estimates, shares plummet
Dialysis firm DaVita projected annual profit below estimates on Thursday due to rising patient care costs, sending its shares down 11% in after-hours trading.
DVA Q4 Estimates Unchanged Before Earnings: How to Play the Stock?
Continued strength in RPT is likely to have boosted DaVita's top line in the fourth quarter despite supply challenges weighing on its performance.
DaVita HealthCare (DVA) Increases Yet Falls Behind Market: What Investors Need to Know
The latest trading day saw DaVita HealthCare (DVA) settling at $177.35, representing a +0.16% change from its previous close.
4 Stocks Trading Near 52-Week High With Room to Rise Further
Investors target stocks that have been on a bullish run lately. Stocks like ENS, DVA, REVG and PAA are seeing price strength and the momentum is likely to continue.
DaVita HealthCare (DVA) Ascends While Market Falls: Some Facts to Note
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $173.77, denoting a +0.32% change from the preceding trading day.
DaVita HealthCare (DVA) Upgraded to Strong Buy: Here's Why
DaVita HealthCare (DVA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
